Pfizer Receives European Approval for Prevenar 13
Pfizer on Friday announced that it received European approval for its pneumoccal vaccine, Prevenar 13, for children. The bacterium can cause pneumonia, middle ear infections, meningitis, and blood infections.
Friday, December 11, 10:31 AM ET
The drug was actually developed by Wyeth, which was bought by Pfizer in a $68 billion deal earlier this year. The original vaccine developed by Wyeth was the company's second best selling drug, with $2.7 billion in revenue in 2008. The old version of the vaccine blocked seven versions of the bacteria, while the new one blocks thirteen.
There has been much consolidation within the pharmaceutical sector in 2009, with the $41.1 billion merger of Merck and Schering-Plough just recently completed.
For MarketNewsVideo.com, I'm Justin Shackil.